RXi Pharmaceuticals Corporation (RXII) EPS Estimated At $-0.96

March 15, 2018 - By Migdalia James

 RXi Pharmaceuticals Corporation (RXII) EPS Estimated At $ 0.96

Analysts expect RXi Pharmaceuticals Corporation (NASDAQ:RXII) to report $-0.96 EPS on March, 29.They anticipate $5.04 EPS change or 84.00 % from last quarter’s $-6 EPS. After having $-1.10 EPS previously, RXi Pharmaceuticals Corporation’s analysts see -12.73 % EPS growth. The stock increased 42.19% or $1.35 during the last trading session, reaching $4.55. About 1.00 million shares traded or 306.49% up from the average. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since March 15, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $10.78 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The company's clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

More notable recent RXi Pharmaceuticals Corporation (NASDAQ:RXII) news were published by: Prnewswire.com which released: “RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15 …” on August 09, 2017, also Smallcapnetwork.com with their article: “RXi Pharmaceuticals Corp: Building a Foundation for a Breakout” published on November 18, 2016, Prnewswire.com published: “RXi Pharmaceuticals Announces Reverse Stock Split” on January 05, 2018. More interesting news about RXi Pharmaceuticals Corporation (NASDAQ:RXII) were released by: Prnewswire.com and their article: “RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New …” published on January 09, 2017 as well as Prnewswire.com‘s news article titled: “RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire …” with publication date: October 12, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: